Sareum Holdings plc, a clinical-stage biotechnology company, has announced significant leadership changes. Co-founder and CEO Dr. Tim Mitchell will transition to a part-time role as Chief Operating Officer (COO), continuing to serve on the board of directors. Dr. Stephen Parker, currently the firm’s non-executive chairman, will step into the role of executive chairman. Sareum is seeking to appoint a new CEO in alignment with its future strategy. Dr. Mitchell expressed optimism about his new role and continuing to support the company’s mission. He highlighted the positive data from the Phase 1 clinical trial of Sareum’s lead product, SDC-1801, as a solid foundation for future developments. Additionally, Clive Birch has been appointed as senior independent director. Dr. Parker lauded Dr. Mitchell’s 20 years of contributions and expressed excitement about navigating Sareum through this pivotal phase.

Biotechnology, Medical Technology (MedTech),United Kingdom